ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026)

ImmunityBio (IBRX) has 10 years of Other Operating Expenses data on file, last reported at $67.6 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $67.6 million, up 39.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $353.0 million (down 18.14% YoY), and the FY2025 annual result was $366.4 million, up 3.79% from the prior year.
• Other Operating Expenses slipped to $67.6 million in Q1 2026 per IBRX's latest filing, from $101.5 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $360.7 million in Q4 2023 and troughed at $681000.0 in Q4 2022.
• A 5-year average of $112.6 million and a median of $93.4 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Operating Expenses jumped 52862.11% in 2023, then slumped 48.82% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $681000.0 in 2022, then jumped by 52862.11% to $360.7 million in 2023, then tumbled by 45.03% to $198.3 million in 2024, then sank by 48.82% to $101.5 million in 2025, then plunged by 33.35% to $67.6 million in 2026.
• Business Quant data shows IBRX's Other Operating Expenses at $67.6 million in Q1 2026, $101.5 million in Q4 2025, and $87.1 million in Q3 2025.